Genetic analysis ( DrugBank: - )
6 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
| 85 | Idiopathic interstitial pneumonia | 1 |
| 90 | Retinitis pigmentosa | 1 |
| 93 | Primary biliary cholangitis | 1 |
| 94 | Primary sclerosing cholangitis | 1 |
| 96 | Crohn disease | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02422732 (ClinicalTrials.gov) | March 2009 | 27/3/2015 | Functional Imaging and Reading Deficit in Children With NF1 | Functional Magnetic Resonance Imaging and Reading Deficit in Children With NF1 Children | Neurofibromatosis Type 1 | Other: Neuropsychological assessments;Radiation: morphological and functional MRI (fMRI);Genetic: genetic analysis | University Hospital, Toulouse | NULL | Completed | 8 Years | 12 Years | Both | 25 | N/A | France |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03211507 (ClinicalTrials.gov) | May 1, 2017 | 2/5/2017 | Idiopathic Pulmonary Fibrosis Job Exposures Study | Idiopathic Pulmonary Fibrosis Job Exposures Study | IPF;Idiopathic Pulmonary Fibrosis | Other: Computer-assisted telephone interview;Genetic: Genetic analysis | Imperial College London | Wellcome Trust;University Hospital Southampton NHS Foundation Trust;Imperial College Healthcare NHS Trust;Heart of England NHS Foundation Trust;Liverpool University Hospitals NHS Foundation Trust;Papworth Hospital NHS Foundation Trust;Nottingham University Hospitals NHS Trust;University Hospital of South Manchester;Guy's and St Thomas' NHS Foundation Trust;North Bristol NHS Trust;The Leeds Teaching Hospitals NHS Trust;Newcastle-upon-Tyne Hospitals NHS Trust;Royal Devon and Exeter NHS Foundation Trust;Somerset NHS Foundation Trust;Royal Infirmary of Edinburgh;Morriston Hospital;Aberdeen Royal Infirmary;Worcestershire Acute Hospitals NHS Trust;University Hospital Birmingham NHS Foundation Trust;Portsmouth Hospitals NHS Trust;Norfolk and Norwich University Hospitals NHS Foundation Trust;Glasgow Royal Infirmary | Completed | N/A | N/A | Male | 960 | United Kingdom |
90. Retinitis pigmentosa
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01235624 (ClinicalTrials.gov) | March 2009 | 4/11/2010 | Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes | Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes | Autosomal Dominant Retinitis Pigmentosa | Genetic: genetic analysis | University Hospital, Montpellier | Ministry of Health, France | Completed | 5 Years | 80 Years | Both | 1161 | N/A | France |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01161953 (ClinicalTrials.gov) | March 2002 | 12/7/2010 | Genetic Epidemiology of Primary Biliary Cirrhosis (PBC) | Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC). | Primary Biliary Cirrhosis | Genetic: Genetic Analysis | Mayo Clinic | NULL | Active, not recruiting | 18 Years | 90 Years | All | 1500 | United States |
94. Primary sclerosing cholangitis
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01161992 (ClinicalTrials.gov) | March 2002 | 12/7/2010 | Genomics of Primary Sclerosing Cholangitis (PSC) | P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies. | Primary Sclerosing Cholangitis (PSC) | Genetic: Genetic Analysis | Mayo Clinic | NULL | Active, not recruiting | 5 Years | 90 Years | All | 1500 | United States |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02851134 (ClinicalTrials.gov) | April 2015 | 7/6/2016 | Search for New Genetic Mutations Major Effect in Crohn's Disease | Search for New Genetic Mutations Major Effect in Crohn's Disease | Crohn Disease | Genetic: genetic analysis;Biological: blood and stools samples | University Hospital, Lille | NULL | Completed | 5 Years | 80 Years | All | 20 | France |